Tilray Clocks 43% Sales Growth In Q1

Tilray Inc TLRY has reported Q1 FY22 sales of $168 million, +43% Y/Y, missing the consensus of $172.6 million.
The increase was driven by a 38% Y/Y growth in net cannabis revenue to $70 million.
Q1 EPS loss $(0.08) came in line with expectations.
Tilray reported a wider operating loss of $(68.5) million compared to $(8.5) million in the prior-year quarter, primarily due to amortization and transaction costs.
Adjusted EBITDA reached $12.7 million, +58% Y/Y. Adjusted EBITDA normalized for Aphria’s production costs is approximately $17 million.
Gross profit increased 46% to $51 million from $35 million in the prior year quarter. Adjusted gross margin in the cannabis segment was at 43%.
The company is on track for at least $80 million in cost savings from Aphria and Tilray business combination synergies.
Related: Tilray CEO Received Nearly $30M In Compensation In Calendar 2021, $13.2M In Cash Bonuses...So Far.
Price Action: TLRY stock is up 0.46% at $10.84 during the premarket session on the last check Thursday.

Earnings Calendar